The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Paradigm Biopharmaceuticals (PAR) activates its first trial site in the United Kingdom for a third-phase trial of its Zilosul treatment for knee osteoarthritis
  • The news comes after the company received UK regulatory and ethics approvals to proceed with the phase three clinical trial
  • Paradigm plans to activate seven sites altogether across the UK, with the remaining locations due to be launched in the coming months
  • Meanwhile, the company’s same clinical trial has received regulatory approval from Health Canada, joining its previous approvals from the US FDA and the Australian TGA
  • Paradigm Biopharmaceuticals last traded at $1.05 on July 5

Paradigm Biopharmaceuticals (PAR) has activated its first trial site in the United Kingdom for a third-phase trial of its Zilosul treatment for knee osteoarthritis (OA).

The news comes after the company received UK regulatory and ethics approvals to proceed with the phase three clinical trial.

The study aims to measure the change in pain and function of patients with OA following injections of pentosan polysulfate sodium (PPS), compared with subcutaneous injections of placebo.

With the first site at the University of Leeds now active, Paradigm said it would look to begin participant screening and enrolment imminently.

Paradigm plans to activate seven sites altogether across the UK, with the remaining locations due to be activated in the coming months.

Meanwhile, the company’s same clinical trial has received regulatory approval from Health Canada.

An ethics submission was made to the research ethics board in Canada, with approval still pending. Once the company gains the approval, Paradigm said it will begin setting up clinical sites and enrolling patients for the study, with up to ten testing sites to be activated across the North American country.

The phase three trial now holds approvals from the US FDA, the UK Medicines and Healthcare products Regulatory Agency (MHRA), Health Canada, and the Australian TGA.

Paradigm Chief Medical Officer Donna Skerrett said the company was pleased to be moving forward with regulatory approval within another planned jurisdiction for the program.

“The interaction with Health Canada was positive throughout the regulatory process, and the company looks forward to announcing anticipated ethics approval and subsequent participant recruitment in Canada,” Dr Skerrett said.

“Equally, the achievement by the Paradigm team to activate participant recruitment in the UK highlights Paradigm’s ongoing execution of activities for this global phase three trial in knee OA.”

Paradigm Biopharmaceuticals last traded at $1.05 on July 5.

PAR by the numbers
More From The Market Online

Week 13 Wrap: Easter bunny delivers new all time high for ASX200

Another week, another all time high. The ASX200 clocked 7,901pts on Thursday for the first time…
The Market Online Video

Market Close: Green lights up on ASX for Easter hunt go

The ASX200 closed the day in record territory - nearly a per cent up with every…

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Market Update: ASX glows red hot with another hit record

The ASX200 is trading up, hitting a new high of 7901 point and eclipsing the last…